Strong chemotherapy fights cancer. But it can also put you at risk for infection—and that can disrupt your cancer treatment plan.[1]

Neulasta® Onpro® helps you fight the risk of infection from home and reduces your risk of being hospitalized.[2,*]



More than 1.6 million patients
have used Neulasta® Onpro® globally[3]

*If, for any reason, you believe you did not receive your full dose of Neulasta® or that your on-body-injector (OBI) is not working correctly, immediately contact your healthcare provider, as an incomplete dose could increase infection risk.

Indication
Neulasta® is a prescription medicine used to help reduce the chance of infection due to a low white blood cell count, in people with certain types of cancer (non-myeloid), who receive anti-cancer medicines (chemotherapy) that can cause fever and low white blood cell count.

Important Safety Information
Do not take Neulasta® if you have had a serious allergic reaction to pegfilgrastim or filgrastim.

Please read the additional Important Safety Information on pages 28-29.

Neulasta® (pegfilgrastim) injection Onpro® kit

Introduction

Learn how you could pay

$5 or less per dose*

*For eligible commercially insured patients, up to annual limit.

Being diagnosed with cancer can be overwhelming. If your treatment plan includes strong chemotherapy, this guide can help.

On the following pages, you'll learn how Neulasta® can help reduce the risk of infection, and how Neulasta® Onpro® is designed to let you stay at home, without having to return to your doctor for another appointment.

Already using Neulasta® Onpro®? Find practical information about using the product on pages 12-15.

TABLE OF CONTENTS

2 Introduction
4 Chemo and Your White Blood Cells
6 How Neulasta® Works
8 Stay Home With Neulasta® Onpro®
10 Common Challenges
12 Your Neulasta® Onpro® Device
14 Overview for Using Neulasta® Onpro®
16 Fighting the Risk of Infection
18 Questions You Can Ask Your Doctor
20 What to Expect
22 Financial Resources
24 Paying for Neulasta® Onpro®
26 Things to Know About Neulasta® Onpro®
28 Important Safety Information

Important Safety Information

Before you receive Neulasta®, tell your healthcare provider about all of your healthcare conditions, including if you:

- Have a sickle cell disorder
- Have had severe skin reaction to acrylic adhesives
- Are allergic to latex – The needle cap on the prefilled syringe contains dry natural rubber (derived from latex).
- Have kidney problems
- Are pregnant or plan to become pregnant. It is not known if Neulasta® may harm your unborn baby.
- Are breastfeeding or plan to breastfeed. It is not known if Neulasta® passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Please read the additional Important Safety Information on pages 28-29.

Chemo and Your White Blood Cells

Strong chemotherapy puts your body at risk for infection that can disrupt your cancer treatments[1]

Chemotherapy works by killing fast-growing cancer cells. One of the side effects of chemotherapy is that it can decrease the number of white blood cells in your body. Having a low white blood cell count can weaken your immune system which increases your risk of infection.[4]

About febrile neutropenia and how it can derail your cancer treatment

A low white blood cell count is called neutropenia. When combined with a fever, it's called febrile neutropenia (FN)—and it may be a sign that you have an infection which is one of the most serious side effects of strong chemotherapy. In fact, based on a study of patient data from 2007-2010, more than 80% of US patients with febrile neutropenia require hospitalization.[5]

>80%
of patients with FN require hospitalization[5]

How Neulasta® Works

Pegfilgrastim is a granulocyte colony-stimulating factor (G-CSF) injection which is prescribed to prevent febrile neutropenia (FN).[6] Neulasta® has been used in over 1.6M patients globally.[3,*] Neulasta® offers Onpro®, the first on-body-injector (OBI), designed to automatically deliver your Neulasta® at the right time.†

†If, for any reason, you believe you did not receive your full dose of Neulasta® or that your OBI is not working correctly, immediately contact your healthcare provider, as an incomplete dose could increase infection risk.

Next-day Neulasta® reduced the incidence of FN by 94% and FN-related hospitalizations by 93%

A study of 928 patients with breast cancer showed that when given once every chemotherapy cycle, Neulasta® helped protect against the risk of infection and reduced hospitalizations. 17% of patients got infections when not treated with Neulasta®—while only 1% of patients got infections when treated with Neulasta®, a 94% reduction. 14% of patients were hospitalized when not treated with Neulasta®—while only 1% of patients treated with Neulasta® were hospitalized, a 93% reduction.[2]

in febrile neutropenia



in FN-related hospitalizations

*March 2015 to April 2024

Please read the additional Important Safety Information on pages 28-29.

Using next-day Neulasta® from your very first cycle of chemo

A study of patients with different types of cancer showed that more patients who received Neulasta® stayed on their chemotherapy regimen than patients who did not receive a white blood cell booster.[7]

Neulasta® Onpro® can help ensure that you stay on track with your chemotherapy regimen[7]

Important Safety Information

What are the possible serious side effects of Neulasta®?

Spleen Rupture. Your spleen may become enlarged and can rupture while taking Neulasta®. A ruptured spleen can cause death. Call your healthcare provider right away if you have pain in the left upper stomach area or left shoulder tip area.

Please read the additional Important Safety Information on pages 28-29.



More than 1.6 million patients have used Neulasta® Onpro® globally[3]

Neulasta® Onpro® reduces the risk of febrile neutropenia without having to go back to the doctor's office[6]

Today with Neulasta® Onpro®, most patients can spend the day after strong chemotherapy at home. It is hard for some patients to return to their doctor the next day to receive Neulasta®. Missing a dose of Neulasta® can increase your risk of febrile neutropenia.[5,6]

95% of patients would choose Onpro® again[8]

Before your first round of strong chemo, ask your doctor if Neulasta® Onpro® can be part of your treatment plan.

Important Safety Information

A serious lung problem called Acute Respiratory Distress Syndrome (ARDS). Call your healthcare provider or get emergency medical help right away if you have shortness of breath with or without a fever, trouble breathing, or a fast rate of breathing.

Please read the additional Important Safety Information on pages 28-29.

Neulasta® Onpro® May Be Able to Help With Common Challenges

For many patients, there's no place like home the day after chemo. There's no reason to make trips back to the doctor's office if you can stay at home instead. Ask your doctor if Neulasta® Onpro® is right for you.

Neulasta® Onpro® may be right for you if you:[6]

- Are an adult
- Are comfortable with the Patient Instructions for Use
- Have no allergies to acrylics

Struggle to get transportation

For some, getting a ride can be difficult

Live far away

Driving is part of the time you spend going to a doctor's appointment

One less trip back to the doctor's office

Neulasta® Onpro® was designed so you can stay home* to get your dose

Bad weather

Avoid the elements and dangerous conditions

Chemo before holidays and weekends

Chemo on a day before next-day office closings

*If, for any reason, you believe you did not receive your full dose of Neulasta® or that your OBI is not working correctly, immediately contact your healthcare provider, as an incomplete dose could increase infection risk.

Important Safety Information

Serious Allergic Reactions. Neulasta® can cause serious allergic reactions. These reactions can cause a rash over your whole body, shortness of breath, wheezing, dizziness, swelling around your mouth or eyes, fast heart rate and sweating.

Please see pages 26-27 for additional important information.

Please read the additional Important Safety Information on pages 28-29.

Your Neulasta® Onpro® Device

Right after your strong chemotherapy treatment, your healthcare provider will apply the OBI to your skin. The OBI is designed to automatically deliver your Neulasta® dose over 45 minutes, approximately 27 hours after activation. **Check the status light and fill indicator to confirm your dose delivery before removing and disposing of the OBI as instructed in the Patient Instructions for Use.**



Flashing green: OBI is working properly. This light flashes more quickly during dose delivery.

Solid green (or turned off): Medication delivery should be complete. Check to see if the fill indicator reads "empty" and there is no noticeably wet adhesive.

Flashing red: OBI error–call your healthcare provider immediately.

Remember: When OBI beeps, check the status light.

Audio

If you hear beeping at any time, check the status light. If it is flashing red, call your healthcare provider right away as you may need a replacement dose.

When dose delivery is complete, a long beep will sound, and the status light will turn solid green.

Cannula Window

Allows you to view the cannula (a short, soft tube) that your Neulasta® passes through during the 45-minute dose delivery.

Status Light

Adhesive Pad

The pad attaches the OBI directly to the skin on the back of your arm or abdomen.

Fill Indicator

The black line should be at FULL until the OBI starts delivering your dose of Neulasta®. The black line should be at EMPTY when your Neulasta® delivery is complete.

The summary does not replace the Patient Instructions for Use. If you are using Neulasta® Onpro®, it's important that you review the Patient Instructions for Use, and call your doctor if you have any questions.

Important Information

While the OBI is in place you should avoid:

- Traveling, driving or operating heavy machinery during hour 26 through hour 29 after the OBI is applied.
- Sleeping on the OBI or applying pressure on the OBI. The OBI may not work properly.
- Bumping the OBI or knocking it off your body.

Please see pages 28-29 for additional important information.

Please read the additional Important Safety Information on pages 30-31.

Overview for Using Neulasta® Onpro®

What to expect when using Neulasta® Onpro®

This information is a summary and does not replace the Patient Instructions for Use. It's important that you thoroughly review the Patient Instructions for Use. These instructions cover everything you need to know about the OBI. If you have any questions, please contact your healthcare provider.

For a more secure fit, an adhesive extender that fits around the OBI called a PodPal™ may be added by your doctor or nurse if they deem it appropriate.

Important Safety Information

If you have an allergic reaction during the delivery of Neulasta®, remove the on-body-injector for Neulasta® by grabbing the edge of the adhesive pad and peeling off the on-body-injector. Get emergency medical help right away.

At the doctor's office

On the same day of your chemo, your healthcare provider will prepare an area of your skin and apply the OBI.



Abdomen



Back of upper arm

Applying the OBI

Once your doctor confirms that the OBI is properly applied to your skin, you can go home.

For the next 27 hours, occasionally check the status light for at least 10 seconds. If the status light is flashing green, it is okay.

Important Safety Information

Sickle Cell Crises. You may have a serious sickle cell crisis, which could lead to death, if you have a sickle cell disorder and receive Neulasta®.

Please read the additional Important Safety Information on pages 30-31.

Fighting the Risk of Infection

Do all you can to reduce the risk of infection

During strong chemotherapy, you may be at risk for infection. There may be ways you can help protect yourself.

Here are some things you can do:[10]

- Wash your hands frequently with soap and warm water. This is especially important after you use the toilet and before cooking and eating.
- Avoid people who have diseases, such as colds or the flu, that you can catch.
- Clean cuts and scrapes right away with warm water and soap. Cover with a bandage. Ask your doctor and care team if using antibiotic creams is right for you.
- Avoid crowds where germs can be rampant.
- Be careful not to cut or nick yourself. Use an electric shaver instead of a razor. Wear protective gloves when gardening or cleaning to avoid cuts and scrapes.

Look out for signs of infection

It's very important to tell your doctor or nurse if you experience any of the following:[10]

- Fever
- Any new area of redness, tenderness, or swelling
- Pus or yellowish discharge from an injury or other location
- New cough or shortness of breath
- New abdominal (belly) pain
- Shaking chills that may be followed by sweating
- Burning or pain when passing urine
- Sore throat
- Sores or white patches in the mouth

Important Safety Information

Kidney injury (glomerulonephritis). Neulasta® can cause kidney injury. Call your healthcare provider right away if you develop any of the following symptoms: swelling of your face or ankles, blood in your urine or dark colored urine, or you urinate less than usual.

Please read the additional Important Safety Information on pages 28-29.

Questions You Can Ask Your Doctor

Any questions? Ask your doctor

It's important that you feel free to talk with your doctor or nurse about your treatment at any time. Asking questions can go a long way toward helping clear up any confusion you may have.

And because another set of ears can be helpful, you may want to bring a friend or family member to doctor appointments.

The following are some questions you may want to ask:

- What type of chemotherapy am I receiving?
- Am I at risk for infection?
- What could happen if I get a serious infection?
- Should Neulasta® be part of my treatment plan?
- How long will I have to use Neulasta®?
- Is Neulasta® Onpro® an option for me?
- Does my insurance cover Neulasta® or Neulasta® Onpro®?

Order your FREE disposal container today

Visit Neulasta.com/Resources

Important Safety Information

Increased white blood cell count (leukocytosis). Your healthcare provider will check your blood during treatment with Neulasta®.

Please read the additional Important Safety Information on pages 30-31.

Overview for Using Neulasta® Onpro®



It is important that you thoroughly review the Patient Instructions for Use. These instructions cover everything you need to know about the OBI. The information in this brochure does not replace the Patient Instructions for Use. Please contact your healthcare provider if you have any questions.

What to expect at home

While wearing Neulasta® Onpro® at home, you'll need to do a few things.

Check the light; listen for a beep: Check the status light occasionally to make sure it flashes green. Your OBI will beep when it needs your attention.

If the light flashes red, call your healthcare provider immediately.

On the day of delivery

1. **Mark your calendar:** Know when your Neulasta® delivery is expected to start. A caregiver should be with you the first time you receive Neulasta® with the OBI. If the OBI is on the back of your arm, always have a caregiver with you to monitor the OBI.
2. **Dose delivery begins:** During delivery, the green light will flash. Dose delivery takes around 45 minutes to complete.
3. **Listen for 1 long beep:** Once dose delivery is complete, you will hear one long beep, and the light will turn solid green (or the light will turn off).
4. **Confirm dose delivery:** The black line on your OBI fill indicator will be on empty after your dose delivery is complete.
5. **Remove OBI and dispose:** Slowly peel off the OBI, and use the free Sharps Disposal Container Program to help you easily and safely dispose of the OBI.

To order your FREE disposal container, call 1-844-MYNEULASTA or visit Neulasta.com/Resources

Important Information

Keep the OBI at least 4 inches away from electrical equipment such as cellphones, cordless telephones, microwaves, and other common appliances. If the OBI is too close to electrical equipment, it may not work correctly and can lead to a missed or incomplete dose of Neulasta®.

Please see pages 26-27 for additional important information.

Please read the additional Important Safety Information on pages 28-29.

Financial Support

Amgen® SupportPlus Co-Pay Program

The Amgen SupportPlus Co-Pay Program may help eligible patients with private or commercial insurance lower their out-of-pocket costs.

- Pay as little as **$0* out-of-pocket** for each dose
- Can be applied to deductible, co-insurance, and co-payment*
- **No income eligibility** requirement

What if I don't have private or commercial insurance (eg, self-purchased or through an employer)?

Amgen SupportPlus can provide information about independent nonprofit foundations that may be able to help.†

Learn more about the ways Amgen SupportPlus can help you access your prescribed medication.

Visit AmgenSupportPlus.com to learn more.

Or call Amgen SupportPlus at [866-264-2778]
Monday - Friday [9:00] am – [8:00] pm ET to learn more.

*Eligibility criteria and program maximums apply. See AmgenSupportPlus.com/copay for full Terms and Conditions.

†Eligibility for resources provided by independent nonprofit patient assistance programs is based on the nonprofit's criteria. Amgen has no control over these programs and provides information as a courtesy only.

AMGEN® Support+

We're right here, right when you need us

Personalized patient support designed for you.

Amgen® Nurse Partners

Dedicated Amgen® Nurse Partners* can offer supplemental support to help you on your treatment journey, including:

- Guidance on resources that may help lower out-of-pocket medication costs
- Assistance to help you stay on track with your medication
- Answers to your questions about Amgen SupportPlus

Get connected with a dedicated Amgen Nurse Partner by enrolling in Amgen SupportPlus:

Download and complete the Amgen SupportPlus Enrollment Form found on AmgenSupportPlus.com and give it to your doctor to complete and fax to 1-888-407-9787.
Call 866-264-2778 to enroll by phone.

*Amgen Nurse Partners are only available to patients that are prescribed certain Amgen products. They are not part of your treatment team and do not provide medical advice, nursing, or case-management services. Nurse Partners will not inject patients with Amgen medications. Patients should always consult their healthcare provider regarding medical decisions or treatment concerns.

CALL Amgen SupportPlus

at (866) 264-2778 Monday through Friday, 9 am to 8 pm ET or **visit AmgenSupportPlus.com** to learn how Amgen can help.

Paying for Neulasta® Onpro®

Insurance Coverage for Neulasta® Onpro®



Across all insurance types, a majority of patients pay **$5 or less per dose*** for Neulasta Onpro.[11]

Regardless of the type of insurance you have, a **majority of commercial and Medicare insurance plans† have coverage** for Neulasta Onpro.[12]

*These data are based on paid claims data from national data providers for the period from 01/01/23 through 12/31/23. Your actual cost may vary depending on your dose, insurance coverage, and eligibility for support programs. Talk to your insurance provider for specific information about your prescription coverage.

†These data are based on insurance claims from national data providers through June 4, 2024. Talk to your insurance provider for specific information about your prescription coverage.

With financial support resources and other helpful patient support services, we are here to help you along the way.

AMGEN® Support+

We're right here, right when you need us.

CALL Amgen SupportPlus

at (866) 264-2778 Monday through Friday, 9 am to 8 pm ET or **visit AmgenSupportPlus.com** to learn how Amgen can help.

Things to Know About Neulasta® Onpro®

- See the Instructions for Use for the OBI for information about the OBI your doctor has chosen.
  - Know the time that delivery of your dose of Neulasta® is expected to start.
  - Avoid traveling, driving, or operating heavy machinery during hour 26 through hour 29 after the OBI is applied. Avoid activities and places that may interfere with monitoring during the 45-minute period that Neulasta® is expected to be delivered by the OBI, and for 1 hour after delivery.
- A caregiver should be with you the first time that you receive Neulasta® with the OBI.
- If placed on the back of the arm, a caregiver must be available to monitor the status of the OBI.
- If you have an allergic reaction during the delivery of Neulasta®, remove the OBI by grabbing the edge of the adhesive pad and peeling off the OBI. Get emergency medical help right away.
- You should only receive a dose of Neulasta® on the day your healthcare provider tells you.
- You should not receive your dose of Neulasta® any sooner than 24 hours after you finish receiving your chemotherapy. The OBI is programmed to deliver your dose about 27 hours after your healthcare provider places the OBI on your skin.
- Do not expose the OBI to the following because the OBI may be damaged, and you could be injured:
  - Diagnostic imaging (eg, CT scan, MRI, ultrasound, X-ray)
  - Radiation treatment
  - Oxygen-rich environments, such as hyperbaric chambers
- Avoid airport X-ray scans. Request a manual pat-down instead. Use care during a manual pat-down to help prevent the OBI from being accidentally removed.
- Keep the OBI at least 4 inches away from electrical equipment such as cell phones, cordless telephones, microwaves, and other common appliances. If the OBI is too close to electrical equipment, it may not work correctly and can lead to a missed or incomplete dose of Neulasta®.
- The OBI is for adult patients only.
- If your OBI is not working properly, you may miss your dose or you may not receive your full dose of Neulasta®. If you miss your dose or do not receive your full dose of Neulasta®, you may have an increased risk of developing fever or infection.
- Call your healthcare provider right away, as you may need a replacement dose, if any of the following occur:
  - OBI for Neulasta® comes off before or during a dose delivery. Do not re-apply it.
  - OBI for Neulasta® is leaking.
  - Adhesive on your OBI for Neulasta® becomes noticeably wet (saturated) with fluid, or there is dripping. This may mean that Neulasta® is leaking out of your OBI for Neulasta®. If this happens you may only receive some of your dose of Neulasta®, or you may not receive a dose at all.
  - OBI for Neulasta® status light is flashing red.

Please review the Patient Instructions for Use for instructions and information about the OBI. Discuss any questions you have with your healthcare provider. The information in this guide is intended as a summary. It is not intended to replace any instructions from your healthcare provider or the Instructions for Use which came packaged with the OBI.

Please read additional Important Safety Information on pages 28-29.

Important Safety Information

Do not take Neulasta® if you have had a serious allergic reaction to pegfilgrastim or filgrastim.

Before you receive Neulasta®, tell your healthcare provider about all of your healthcare conditions, including if you:

- Have a sickle cell disorder
- Have had severe skin reaction to acrylic adhesives
- Are allergic to latex – The needle cap on the prefilled syringe contains dry natural rubber (derived from latex).
- Have kidney problems
- Are pregnant or plan to become pregnant. It is not known if Neulasta® may harm your unborn baby.
- Are breastfeeding or plan to breastfeed. It is not known if Neulasta® passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible serious side effects of Neulasta®?

- **Spleen Rupture.** Your spleen may become enlarged and can rupture while taking Neulasta®. A ruptured spleen can cause death. Call your healthcare provider right away if you have pain in the left upper stomach area or left shoulder tip area.
- **A serious lung problem called Acute Respiratory Distress Syndrome (ARDS).** Call your healthcare provider or get emergency medical help right away if you have shortness of breath with or without a fever, trouble breathing, or a fast rate of breathing.
- **Serious Allergic Reactions.** Neulasta® can cause serious allergic reactions. These reactions can cause a rash over your whole body, shortness of breath, wheezing, dizziness, swelling around your mouth or eyes, fast heart rate and sweating.

If you have an allergic reaction during the delivery of Neulasta®, remove the on-body-injector for Neulasta® by grabbing the edge of the adhesive pad and peeling off the on-body-injector. Get emergency medical help right away.

- **Sickle Cell Crises.** You may have a serious sickle cell crisis, which could lead to death, if you have a sickle cell disorder and receive Neulasta®.
- **Kidney injury (glomerulonephritis).** Neulasta® can cause kidney injury. Call your healthcare provider right away if you develop any of the following symptoms: swelling of your face or ankles, blood in your urine or dark colored urine, or you urinate less than usual.
- **Increased white blood cell count (leukocytosis).** Your healthcare provider will check your blood during treatment with Neulasta®.
- **Decreased platelet count (thrombocytopenia).** Your healthcare provider will check your blood during treatment with Neulasta®. Tell your healthcare provider if you have unusual bleeding or bruising during treatment with Neulasta®. This could be a sign of decreased platelet counts, which may reduce the ability of your blood to clot.
- **Capillary Leak Syndrome.** Neulasta® can cause fluid to leak from blood vessels into your body's tissues. This condition is called "Capillary Leak Syndrome" (CLS). CLS can quickly cause you to have symptoms that may become life-threatening. Get emergency medical help right away if you develop any of the following symptoms:
  - swelling or puffiness and are urinating less than usual
  - trouble breathing
  - swelling of your stomach area (abdomen) and feeling of fullness
  - dizziness or feeling faint
  - a general feeling of tiredness
- **Myelodysplastic syndrome and acute myeloid leukemia.** If you have breast cancer or lung cancer, when Neulasta® is used with chemotherapy and radiation therapy, or with radiation therapy alone, you may have an increased risk of developing a precancerous blood condition called myelodysplastic syndrome (MDS) or a blood cancer called acute myeloid leukemia (AML). Symptoms may include tiredness, fever, and easy bruising or bleeding. Call your healthcare provider if you develop these symptoms during treatment with Neulasta®.
- **Inflammation of the aorta (aortitis).** Inflammation of the aorta (the large blood vessel which transports blood from the heart to the body) has been reported in patients who received Neulasta®. Symptoms may include fever, abdominal pain, feeling tired, and back pain. Call your healthcare provider if you experience these symptoms.

The most common side effect of Neulasta® is pain in your bones and in your arms and legs.

These are not all the possible side effects of Neulasta®. Call your healthcare provider for medical advice about side effects. You may report negative side effects to the FDA at **1-800-FDA-1088.**

Please see **Neulasta® Patient Information.**

Neulasta® Injection: 6 mg/0.6 mL in a single-dose prefilled syringe for manual use only.

Neulasta® Injection: 6 mg/0.6 mL in a single-dose prefilled syringe co-packaged with the on-body-injector (OBI) for Neulasta® (Neulasta® Onpro® kit).

Neulasta® is given as an injection under the skin (subcutaneous).

Please see additional Important Safety Information throughout this brochure.

References: 1. Lyman GH. Impact of chemotherapy dose intensity on cancer patient outcomes. *J Natl Compr Canc Netw.* 2009;7(1):99-108. **2.** Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. *J Clin Oncol*. 2005;23(6):1178-1184. **3.** Data on file, Amgen; [1]; 2024. **4.** American Cancer Society. Chemotherapy side effects. https://www.cancer.org/cancer/managing-cancer/treatment-types/chemotherapy/chemotherapy-side-effects.html. Accessed July 16, 2024. **5.** Weycker D, Barron R, Kartashov A, Legg J, Lyman GH. Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings. *J Oncol Pharm Pract.* 2014;20(3):190-198. **6.** Neulasta® (pegfilgrastim) Prescribing Information, Amgen. **7.** Data on file, Amgen; 2017. **8.** Data on file, Amgen; 2016. **9.** Neulasta® (pegfilgrastim) Onpro® kit Healthcare Provider Instructions for Use, Amgen. **10.** American Cancer Society. Watching for and preventing infections. https://www.cancer.org/cancer/managing-cancer/side-effects/infections/preventing-infections-in-people-with-cancer.html. Accessed July 16, 2024. **11.** Data on file, Amgen; 2023. **12.** Data on file, Amgen; [2]; 2024.

Neulasta® (pegfilgrastim) injection Onpro® kit

For more information, please visit Neulasta.com

One Amgen Center Drive
Thousand Oaks, CA 91320-1799
www.amgen.com

AMGEN®